

In the Claims

The pending claims are:

1. (previously presented) A method for reducing alopecia induced by the administration of cyclophosphamide comprising the steps of administering to an individual in need of treatment a therapeutically effective dose of cyclophosphamide and a selenium compound selected from the group consisting of seleno-L-methionine and methylselenocysteine, wherein the alopecia induced by cyclophosphamide is less than the alopecia induced in the absence of the selenium compound.
2. (original) The method of claim 1, wherein the selenium compound is seleno-L-methionine.
3. (original) The method of claim 1, wherein the selenium compound is methylselenocysteine.
4. (previously presented) The method of claim 1, wherein the selenium compound is administered at a time selected from the group consisting of prior to administration of cyclophosphamide, during administration of cyclophosphamide, following administration of cyclophosphamide and a combination thereof.
5. (canceled)
6. (canceled)
7. (previously presented) The method of claim 1, wherein the selenium compound is administered at a dose of 200 μ g/person to 800 μ g/person.

8. (previously presented) A method for using cyclophosphamide at a higher than therapeutic dose comprising the steps of administering to an individual in need of treatment a higher than therapeutic dose of cyclophosphamide and a selenium compound selected from the group consisting of seleno-L-methionine and methylselenocysteine, wherein alopecia induced by cyclophosphamide is reduced with the administration of the selenium compound.

9. (original) The method of claim 8, wherein the selenium compound is seleno-L-methionine.

10. (original) The method of claim 8, wherein the selenium compound is methylselenocysteine.

11. (previously presented) The method of claim 8, wherein the selenium compound is administered at a time selected from the group consisting of prior to administration of cyclophosphamide, during administration of cyclophosphamide, following administration of cyclophosphamide and a combination thereof.

12. (canceled)

13. (canceled)

14. (previously presented) The method of claim 8, wherein the selenium compound is administered at a dose of 200 μ g/person to 3.6 mg/person.